Recent Advanced Stage Hodgkin's Lymphoma News

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 18, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher... Continue Reading

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (December 12, 2014)

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results... Continue Reading

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal... Continue Reading

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma (January 16, 2014)

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant,... Continue Reading

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma (January 2, 2013)

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester... Continue Reading

Similar Overall Survival with ABVD and BEACOPP for Advanced Hodgkin’s Lymphoma (July 25, 2011)

Although the BEACOPP chemotherapy regimen produces better initial tumor control than the commonly used and less toxic ABVD regimen, the two regimens produce similar overall survival among patients with... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

Next Page »